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Abstract
Thyroid cancer is the most common endocrine malignancy. Approximately 70% of
cases of papillary thyroid carcinoma and 50% of poorly differentiated and anaplastic
thyroid carcinoma harbor well-characterized driver mutations and chromosomal
rearrangements that drive tumorigenesis. Molecular profiling has been helpful in
identifying and informing follow-up strategies in tumors with more aggressive
trajectories. Here, we report a case of papillary thyroid cancer (PTC) discovered in a
patient with thyroid nodules with relatively benign ultrasound and fine needle aspira-
tion (FNA) findings. Molecular testing in this patient identified a rare STRN-ALK
fusion in two thyroid nodules with indeterminate and/or benign cytology. This led to
the patient undergoing a thyroid lobectomy and a subsequent confirmation of papil-
lary thyroid carcinoma upon resection. The report highlights the role of comprehen-
sive molecular testing in thyroid lesions of indeterminate cytology.
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1 | INTRODUCTION
Most thyroid malignancies present as solitary thyroid nodules that can
be clinically indistinguishable from benign nodules. Fine needle aspira-
tion (FNA) cytology as a standard diagnostic procedure is a safe, cost-
effective and rapid tool for establishing a diagnosis and an excellent
source of tumor tissue for ancillary studies. Molecular testing has
been a valuable resource for diagnosis and management of patients
with indeterminate cytology.1
Classification of thyroid cancer based on morphological evidence
could be supported by molecular biomarkers, including markers that
interrogate multiple genes using massively parallel sequencing or
next-generation sequencing (NGS). Thyroid cancers are characterized
by molecular alterations, such as activating/inactivating mutations,
rearrangements, and copy number variations in genes responsible for
cell proliferation, differentiation and apoptosis. Papillary thyroid can-
cer (PTC) develops through the activation of the RET/PTC-RAS-
BRAF-ERK axis, with BRAF V600E being the major driver of classical
PTC.2 Other significant variants include TERT promoter, EIFAX muta-
tions and RET rearrangements.2
Chromosomal rearrangements have been identified in PTC and
include those involving RET, BRAF, NRTK1, NTRK3, and ALK.3 Herein
we describe a patient with thyroid nodules where FNA revealed
atypia of unknown significance (AUS) in one nodule and benign
multinodular goiter in a second nodule. Molecular testing of both nod-
ules identified an STRN-ALK fusion. This finding led to a diagnosis of
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PTC on resection of the affected lobe. This case demonstrates the
utility of molecular profiling in aiding diagnosis and management of
thyroid neoplasms with indeterminate histology.
2 | CASE REPORT
A 44 year old woman with medical history significant for ulcerative
colitis, asthma, and ovarian cysts noted pain and difficulty with
swallowing, along with pooling of saliva. Her relevant family history
includes a maternal aunt with thyroid nodules. The patient had no per-
sonal history of radiation exposure. An ultrasound of the soft tissue of
the neck and thyroid revealed a heterogeneous, complex, predomi-
nantly solid hypoechoic nodule containing round coarse calcifications
and measuring 1.7 × 1.4 × 1.1 cm located at the lower pole of the
right lobe of thyroid (Nodule 1). This nodule had low suspicion for
malignancy according to American Thyroid Association (ATA) guide-
lines.4 Ultrasound evaluation also demonstrated an adjacent, more
superiorly located solid, hypoechoic circumscribed right middle pole
nodule measuring 1.0 × 0.8 × 1.2 cm (Nodule 2), with intermediate
suspicion for malignancy according to ATA guidelines.4 An additional
isoechoic solid nodule with a hypoechoic halo, measuring 0.7 × 0.5
× 0.7 cm was found in the mid to upper pole of the right lobe
(Nodule 3). Taken together, ultrasound results were consistent with a
multinodular thyroid gland with three right-sided thyroid nodules and
did not raise strong concern for malignancy. At the time of presenta-
tion, relevant laboratory results including intact PTH, 25-OH
Vitamin D, TSH and Free T4 were within normal limits.
Subsequently, a fine needle aspiration (FNA) biopsy of the larger
two nodules was performed. The right lower pole nodule (Nodule 1)
demonstrated groups of follicular cells with focal cytological atypia,
including mild nuclear enlargement, occasional nuclear grooves with a
background of macrophages, inflammatory cells and scant colloid
(Figure 1A). The findings were consistent with a follicular lesion of
undetermined significance-Bethesda Category III with recommenda-
tion for follow up FNA.5 The specimen was routed for molecular test-
ing. Biopsy results of the right middle pole nodule (Nodule 2) revealed
clusters of follicular cells with Hurthle cell changes arranged in
groups/sheets and singly in a background of macrophages and watery
colloid. Many cyst lining cells were also noted (Figure 1B). These find-
ings were consistent with nodular goiter with cystic degeneration
classified as Bethesda Category II-Benign, with recommendation for
clinical and sonographic follow-up.5
3 | MOLECULAR ANALYSIS
As per the molecular testing algorithm of thyroid FNA specimens at our
institution, DNA extraction from formalin-fixed paraffin-embedded
(FFPE) tissue was performed following the manufacturer's protocol
using the DNeasyTissue kit on the QIAcube (QIAGEN). Extracted DNA
from Nodule 1 underwent testing with a custom targeted Solid Tumor
Panel based on Stem-Loop Inhibition Mediated Amplification
(SLIMamp) technology (Pillar Biosciences) with multiplexed sequencing
performed on the Illumina MiSeq. The following thyroid-relevant genes
of the panel were interrogated for mutations: AKT1(NM_005163 e3),
BRAF(NM_004333 e11,15), CTNNB1(NM_001904 e3,7,8), EIF1AX
(NM_001412 e1,2,6), GNAS(NM_000516 e8,9), HRAS(NM_005343
e2-4), KRAS(NM_004985 e2-4), NRAS(NM_002524 e2-4), PIK3CA
(NM_006218 e2,3,5,7,8,10,14,19,21), PTEN(NM_000314 e1-9),
RET(NM_020975 e10,11,13,15,16), TERT(promoter, NM_198253
5 UTR), TP53(NM_000546 e2,4-10), TSHR(NM_000369 e9-10).
Per standard protocol at our institution, thyroid cases with no
identifiable drivers in the DNA hotspot Panel are reflexed to RNA
analysis from the same tissue with the Archer FusionPlex panel, which
F IGURE 1 A, Nodule 1. Thyroid, right lobe, lower pole,
ultrasound-guided fine needle aspiration biopsy. This specimen
consists of groups of follicular cells with focal cytological atypia,
including mild nuclear enlargement, occasional nuclear grooves. There
is a background of macrophages, inflammatory cells, and scant colloid.
These findings are consistent with a follicular lesion of undetermined
significance. (H&E, 600X). B, Nodule 2. Thyroid, right lobe, middle
pole, ultrasound-guided fine needle aspiration biopsy. This specimen
consists of clusters of follicular cells with Hurthle cell change arranged
in groups/sheets and singly, in a background of macrophages and
watery colloid. Many cyst lining cells are also noted. These findings
are consistent with a nodular goiter with cystic degeneration.
(H&E, 600X)
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is a custom RNA targeted sequencing panel from Archer (Archer,
Boulder, CO) that aims to identify known and novel fusions in lung,
thyroid, brain and gastrointestinal tumors. RNA was extracted using
the ALL-Prep DNA/RNA kit (QIAGEN) followed by targeted sequenc-
ing based on Anchored Multiplex PCR (AMP) technology (Archer,
Boulder, CO). cDNA libraries with molecular barcode adapters were
prepared and sequencing was performed on the Illumina MiSeq plat-
form. Identification of fusion transcripts, exons, and breakpoints was
performed with the Archer Analysis software v6.0.4. Genes in the cus-
tom targeted RNA fusion panel include ALK, AXL, BRAF, EGFR,
FGFR1, FGFR2, FGFR3, MET, MYB, NRG1, NTRK1, NTRK2, NTRK3,
PDGRFA, PPARG, RET, ROS1, THADA. Fluorescence in situ hybridiza-
tion (FISH) analysis was performed using an ALK (2p23) break-apart
probe (Abbott Molecular).
4 | RESULTS/FINDINGS
The targeted DNA hotspot panel did not identify potential driver
mutations in Nodule 1. As per standard protocol in our laboratory, the
sample was reflexed to the RNA fusion panel. This analysis revealed a
fusion between exon 3 of the striatin gene, (STRN) with the canonical
anaplastic lymphoma kinase (ALK) gene breakpoint at exon 20.
(Figure 2A). It was found in 42% of reads and met the quality control
requirements for a confident fusion call as indicated in Table 1.
Quality control requirements for a confident fusion call were as
follows: Number of supporting reads spanning the fusion junction ≥5;
Percentage of supporting reads spanning the fusion junction ≥10%;
Number of unique start sites (SS) for the fusion sequenced specific
primer ≥3. Figure 2B is a representation of the STRN-ALK fusion.
F IGURE 2 A, STRN-ALK fusion. Schematic of STRN-ALK fusion yielding E3:E20 STRN-ALK, wherein STRN is fused with the canonical
breakpoint (exon 20) of the ALK gene. B, JBrowse view of the STRN-ALK fusion. The fusion between exon 3 of STRN and Exon 20 of ALK is
clearly visualized in JBrowse viewer
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The FNA sample from Nodule 1 was exhausted in the process of
the above-mentioned testing, therefore, an FNA sample from Nodule
2 was subject to ALK rearrangement by FISH with the ALK break-
apart probe. Interestingly, this nodule was positive for an ALK fusion,
despite the benign histology on cytological evaluation.
Due to the rarity of the STRN-ALK fusion and previously reported
strong association with malignancy,6 the patient underwent a right
thyroid lobectomy. The left lobe of the thyroid showed a relatively
homogenous echotexture with no nodules; therefore, a total thyroid-
ectomy was not performed. The resection specimen revealed a histo-
pathological diagnosis of multifocal papillary thyroid carcinoma,
classical type in a background of nodular goiter (Figure 3A, B, C) with
tumor, node, and metastasis (TNM) staging of T1bN0. This FFPE tis-
sue sample showed ALK rearrangement by FISH in 42% of cells
(Figure 4) as well as the same STRN-ALK fusion in 93% of reads. The
FFPE tissue that was enriched for tumor by macrodissection had
higher number of reads compared to the pauci-cellular FNA specimen
in nodule 1. The patient was considered low risk for relapse and did
not receive any ALK-targeted therapy. She was started on
levothyroxine for thyroid hormone replacement post-operatively with
a plan for regular sonographic and laboratory follow up. Six months
following surgery, a hypoechoic somewhat spongiform-appearing mid
to upper pole nodule measuring 0.5 × 0.3 × 0.5 cm that was not previ-
ously visualized was seen on follow-up ultrasound. Due to this nod-
ule's small size and benign appearance, sonographic follow up was
scheduled.
5 | DISCUSSION
This fusion represents an intrachromosomal rearrangement involving
the short arm of chromosome 2p22-23, resulting in a fusion of striatin
(STRN), which encodes a calcium-dependent calmodulin-binding pro-
tein with the tyrosine kinase domain of anaplastic lymphoma kinase
(ALK) gene. Similar to the EML4-ALK fusion, STRN-ALK fusion part-
ners are located on the short arm of chromosome 2 (2p22.2 and
2p23, separated by 7.5 Mb), suggesting that the fusion results from
a paracentric inversion. The STRN gene includes four putative
protein-protein interaction domains, which consist of a caveolin-
binding domain, a coiled-coil domain, a calcium dependent
calmodulin-binding domain, as well as the WD-repeat region.6 The
STRN/ALK transcript is composed of the N-terminal caveolin-binding
and coiled-coil domains of STRN fused to the intracellular juxta-
membrane region of ALK, which contains the tyrosine kinase domain.6
This fusion leads to constitutive activation of ALK kinase via ligand-
independent dimerization mediated by the coiled-coil domain of STRN
and subsequent MAPK activation. This fusion also results in a loss of
the transmembrane and extracellular domains of ALK, leading to a loss
of cell membrane anchoring.6 Functional studies in vitro showed that
PCCL3 thyroid follicular cells transfected with STRN-ALK plasmids
demonstrated increased cellular proliferation dependent on ALK
kinase activity and independent of thyroid-stimulating hormone
(TSH).6 In addition, transfected cells also demonstrated a spindle-
shaped and birefringent appearance that is suggestive of a
transformed-like phenotype. in vivo experiments injecting transfected
NIH 3 T3 cells into nude mice confirmed tumorigenicity.6
A screen of 235 cases of well-differentiated PTC revealed a 1.3%
prevalence of the STRN-ALK fusion.6 The fusion occurs more often in
aggressive cancers.6 None of the patients had history of radiation
exposure and all lacked mutations in other known driver genes.6 This
fusion has important clinical significance as the kinase activity of
STRN-ALK and ALK-induced cell growth can be blocked in vitro by
the ALK inhibitors crizotinib and TAE684.6 A survey of the literature
shows that ALK-inhibitors are useful in treating malignancies with the
STRN-ALK rearrangement. A patient with anaplastic thyroid carci-
noma with infiltration beyond the thyroid capsule and four regional
lymph node metastases, who was initially treated with surgery and
radiochemotherapy with poor overall response was found to harbor
an STRN-ALK fusion and showed an excellent clinical response to
crizotinib treatment.7,8 This fusion was also noted in several patients
with non-small cell lung cancer. A patient with metastatic lung adeno-
carcinoma was found to harbor this same STRN-ALK fusion and
TABLE 1 Details for the STRN-ALK fusions found in the patient






























Note: The details of the STRN-ALK fusion identified in Nodule 1 and the resection specimen are shown above, including the chromosomal breakpoint,
fusion sequence, number of supporting reads and start sites. Quality control requirements for a confident fusion call are as follows: Number of supporting
reads spanning the fusion junction ≥5; Percentage of supporting reads spanning the fusion junction ≥10%; Number of unique start sites (SS) for the fusion
sequenced specific primer ≥3.
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showed an excellent clinical, radiographic and molecular response to
treatment with crizotinib.10 In contrast, another patient with meta-
static lung adenocarcinoma harboring an STRN-ALK fusion did not
respond to treatment with alectinib.11 A more recent report describes
the establishment and molecular characterization of a patient-derived
xenograft from a patient harboring the STRN-ALK fusion who pres-
ented with metastatic lung adenocarcinoma.12 This patient was ini-
tially treated with crizotinib with a durable response of four years
until evidence of disease progression with intracerebral metastases.
The patient's therapy was subsequently switched to ceritinib and
whole brain radiation, which resulted in stable disease for at least
26 months at time of most recent follow up.12 Finally, a patient with
malignant peritoneal mesothelioma showed dramatic response follow-
ing treatment with ceritinib.13 These studies highlight the importance
of identification of this particular fusion not only for diagnostic pur-
poses, but also for therapeutic benefit. A targeted multi-gene fusion
panel interrogating a list of relevant genes and enabling discovery of
both known as well as novel fusions should be considered for all cases
of suspected or diagnosed thyroid carcinoma due to the potential for
improved diagnosis, prognosis, as well as for discovery of therapeuti-
cally targetable fusions.
6 | CONCLUSIONS
In summary, we describe a case of a patient with thyroid nodules
wherein fine needle aspiration revealed atypia of unknown signifi-
cance in one nodule and benign multinodular goiter in a second nod-
ule. Subsequent molecular profiling of the FNA specimens revealed
the presence of a fusion between the anaplastic lymphoma kinase
(ALK) and striatin (STRN) genes. This demonstrates the utility of
molecular testing as an adjunct to histopathological evaluation in diag-
nosis and management of thyroid malignancies, as indeterminate and
even benign lesions can harbor transformative fusions with signifi-
cance for patient management.
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F IGURE 3 A, B, C. Thyroid gland, right lobe, lobectomy. The
tumor had papillary architecture (3A) with nuclear features of papillary
thyroid carcinoma such as nuclear enlargement, as well as crowding/
overlapping nuclei, nuclear grooves (3B) and nuclear pseudoinclusions
(3C). Overall histologic findings are consistent with papillary thyroid
carcinoma, classical type (H&E, 2A: 100X, 2B: 400X, 2C: 600X)
F IGURE 4 FISH analysis on FFPE tissue section using ALK break-
apart probe on lobectomy sample. The fused (yellow) signal
represents unrearranged normal copy of ALK (yellow arrow) and
isolated reddish-orange signal is a rearranged ALK (red arrow) copy
with deletion of green (5'ALK) signal
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